Dr. Abelson studies the extrinsic selective pressures and cell-intrinsic mechanisms governing clonal dominance and cell transformation.
Dr. Ailles and her team are focusing on two major research areas: intra-tumoural heterogeneity and epigenetics in clear cell renal cell carcinoma.
Dr. Al-awar, leader of OICR's Drug Discovery group, works to discover and develop new drugs for various cancer types in collaboration with both academic and industry partners.
Dr. Aldape is an OICR associate.
Dr. Awadalla and his team focus on the development of genomics approaches, model-based tools and population-based approaches to study mutation rates, genome biology and cancer.
Dr. Bartlett and his team focus on the development of novel diagnostic approaches to stratified medicine, predominantly in breast and prostate cancer.
Dr. Bedard is working to bring next-generation sequencing to more Ontario cancer patients through the Ontario-wide Cancer TArgeted Nucleic Acid Evaluation (OCTANE) study.
Dr. Bell's lab is developing novel oncolytic virus products that both kill cancer cells while stimulating anti-tumour immunity.
Dr. Boutros' team develops new biomarkers to better personalize cancer treatment using open-source software and novel computational techniques.
Dr. Butler is the clinical lead of OICR's Immuno-oncology Translational Research Initiative (ACTION). His expertise includes clinical trials in a variety of immune therapies.
Dr. Janet Dancey is the leader of the Canadian Cancer Clinical Trials Network and the Canadian Cancer Trials Group.
Dr. Dick’s world-renowned research program centers on the theme that genetic and non-genetic determinants of tumour heterogeneity are linked through stemness. He co-leads OICR's Acute Leukemia Translational Research Initiative.
Dr. Dirks is a pediatric neurosurgeon and senior scientist at the Hospital for Sick Children. He co-leads OICR's Brain Cancer Translational Research Initiative.
Dr. Feilotter focuses on the development of biomarkers to be used in the screening, diagnosis or treatment of human diseases, including cancer.
Dr. Fenster is driven by the opportunity to use technological innovations to meet the challenges of cancer diagnosis and therapy needs. He co-leads OICR's Imaging program.
Dr. Fiume is the CEO of DNAstack, a key leader within the Global Alliance for Genomics and Health and an OICR associate.
Dr. Ferretti is a bioinformatics leader with experience in both large-scale software development and computational genomics.
Dr. Fong is the founder of the International Tobacco Control Policy Evaluation Project. This project's objective is to evaluate the impact of policies designed to control tobacco use.
Dr. Gallinger is the leader of OICR's Pancreatic Cancer Translational Research Initiative (PanCuRx).
Genome Sequence Informatics
GSI assists collaborators in experimental design, as well as the interpretation of the results and the publication of experimental results.
Genome Technologies Platform
Supporting researchers in many applications: FFPE & low-input samples, high volume studies, targeted panels, long read sequencing, single cell sequencing, low variant detection, and much more
The focus of Dr. Grunfeld’s research is the evaluation of access to and quality of cancer care across the cancer control continuum – from screening to end-of-life care.
Dr. Haibe-Kains is an OICR associate that works to develop tools that can mine pharmacogenomic datasets.
Dr. Haider’s research focus is abdominal and pelvic MRI with an interest in therapeutic response assessment and quantitative imaging of cancer.
Dr. Hanna’s research focuses on three translational streams of health services research: quality of care, value of care and access to care.
The overarching goal of Dr. Hirano’s research is to devise novel anti-tumour immunotherapeutic modalities that can cure cancer.
Dr. Hope aims to identify the underlying processes that lead to the transformation of healthy cells into leukemic cells and contribute to the progression of the disease.
Dr. Jamaspishvili is working to identify and validate promising diagnostic and prognostic biomarkers for early prostate cancer.
Kornaga is an OICR associate working in molecular pathology.
Dr. LeBrun’s research group studies perturbations in the regulation of gene transcription that underlie acute lymphoblastic leukemia and other cancers.
Dr. Lupien’s research highlights the need to characterize and understand the role of noncoding regulatory elements as targets of genetic and epigenetic changes in oncogenesis.
Dr. McPherson is an OICR associate specializing in genome technologies.
Dr. Morris is a Senior Investigator and an OICR associate specializing in machine learning and artificial intelligence.
Dr. Nieman is studying the developmental impact of chemotherapy agents with a goal of improved brain development and quality of life in childhood cancer patients.
Dr. Notta is an OICR associate working to decipher new molecular targets that are needed to treat pancreatic cancer.
Dr. Oza co-leads OICR's Ovarian Cancer Translational Research Initiative and specializes in clinical trials for gynecologic cancers.
Dr. Palma's research focuses on new imaging technologies used with radiotherapy to improve tumour targeting and to deliver higher doses of radiotherapy than previously possible.
Dr. Pearson’s lab is working to understand the connection between adult stem cells and cancer by using the freshwater planarian as an in vivo model system.
Dr. Pond’s research interest is in statistical methodologies and analysis of cancer clinical trials, with an aim to facilitate the translation of scientific discoveries into the clinic.
Dr. Pugh is leader of the Princess Margaret-OICR Translational Genomics Laboratory and an OICR associate.
The Reimand Lab develops and applies methods to interpret cancer data using pathway and network information.
The Rottapel Lab uses functional genetic screens (both shRNA and CRISPR/Cas9) to identify novel vulnerabilities in ovarian cancer as a strategy to develop new therapeutic targets.
Dr. Schimmer is the co-leader of OICR's Acute Leukemia Translational Research Initiative. His work focuses on new therapies for leukemia.
Dr. Scholl is focusing on developing an emergent technique for molecular imaging with magnetic resonance.
The Simpson Lab develops algorithms and software for the analysis of high-throughput sequencing data.
Dr. Siu is Co-Principal Investigator of the Ontario-wide Cancer TArgeted Nucleic Acid Evaluation (OCTANE) study.
Dr. Soave is an OICR associate specialized in biostatistics and longitudinal data analysis.
Dr. Stein is the leader of Adaptive Oncology at OICR.
Dr. Taylor is a paediatric neurosurgeon and senior scientist at the Hospital for Sick Children. He co-leads OICR's Brain Cancer Translational Research Initiative.
Translational Genomics Laboratory
TGL enhances rapid access to genomics technologies, and facilitates genomic interpretation and reporting in clinical oncology.
The OICR webdev team designs and builds websites and web applications that enable OICR to present leading-edge cancer research that engages a global community for collaboration.
Dr. Wouters’ lab has identified new signaling pathways that influence how tumours respond to environments with reduced oxygenation.
Dr. Yaffe’s research is directed toward development and improvement of imaging techniques for the earlier detection, diagnosis and treatment of cancer.
Dr. Yung is the Director of Genome Informatics at OICR.
Request an OICR Lab Space
The OICR Labs website empowers OICR researchers and their teams to communicate their goals and share research assets related to their labs. OICR Labs enables full-access GitHub repositories to members to produce any type of webpage, and enables semantic-level search capabilities between lab websites. If you would like your own OICR lab website to be listed above: